Jim Ingram, MD
Allergy & Immunology · Little Rock, ARNPI 1093707176
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,572 of the $62,347 with a category attached, or 66.7%. 33 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 48.2% of the total. Reporting peaked in 2019 at $30,355 and has fallen 92.1% since, to $2,407 in 2025. Among allergy & immunology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 636 payments — averaging $98.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$30K
- Sanofi$22K
- Pfizer$2K
- AstraZeneca$2K
- GSK$2K
- CSL Behring$764
- plus $4K from 27 others
What the payments were for
- Consulting fees$400%
- Speaking & faculty fees$41,57267%
- Travel & lodging$9,23615%
- Food & beverage$11,47718%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 73 | $30,079 |
| Sanofi | 71 | $21,732 |
| Pfizer | 16 | $2,360 |
| AstraZeneca | 75 | $1,909 |
| GSK | 166 | $1,893 |
| CSL Behring | 41 | $764 |
| Grifols USA, LLC | 29 | $633 |
| Novartis | 33 | $536 |
| Genentech USA, Inc. | 26 | $461 |
| Kaleo, Inc. | 20 | $342 |
| Amgen | 15 | $242 |
| Octapharma USA, Inc. | 5 | $239 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $174 |
| LEO Pharma Inc. | 9 | $159 |
| Optinose US, Inc. | 10 | $153 |
| Lilly USA, LLC | 5 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $81 |
| Biocryst US Sales Co., LLC | 3 | $76 |
| Hikma Pharmaceuticals USA | 3 | $57 |
| ADMA Biomanufacturing LLC | 3 | $53 |
| Shire North American Group Inc | 3 | $49 |
| Mylan Specialty L.p. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Boehringer Ingelheim | 2 | $24 |
| Pharming Healthcare, Inc. | 1 | $24 |
| GC Biopharma USA, Inc. | 1 | $20 |
| USWM, LLC | 1 | $20 |
| Alk-abello, Inc | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Kedrion Biopharma, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Greer Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,347 in reported general payments places this provider in the 95th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $131,156 |
| XolairOmalizumab | 24 | $86,783 |
| NucalaMepolizumab | 11 | $37,728 |
| Epinephrine | 121 | $23,556 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $22,312 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $14,628 |
| Arnuity ElliptaFluticasone Furoate | 48 | $11,019 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,953 |
| Azelastine Hcl | 389 | $10,015 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $9,507 |
| DuleraMometasone/Formoterol | 21 | $9,186 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,597 |
| Serevent DiskusSalmeterol Xinafoate | 12 | $4,412 |
| Fluticasone Propionate | 341 | $3,717 |
| Advair DiskusFluticasone Propion/Salmeterol | 22 | $3,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,893 | $202,214275 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,909 | $25,58169 claims |
| Hikma Pharmaceuticals USAEpinephrine | $57 | $23,556121 claims |
| MerckDulera | $16 | $9,18621 claims |
| Boehringer IngelheimSpiriva Respimat | $24 | $5,59712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Little Rock
- Blake ScheerLittle Rock$81K
- Karl SitzLittle Rock$19K
- Stacy GriffinLittle Rock$10K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
- Adam PriceLittle Rock$4K
- Lori KagyLittle Rock$4K
- Gene FranceLittle Rock$2K
- Joshua KennedyLittle Rock$2K
- Meredith DilleyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.